Cdymax (India) Pharma Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 24-06-2024
- Paid Up Capital ₹ 8.88 Cr
as on 24-06-2024
- Company Age 30 Year, 15 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 123.48 Cr
as on 24-06-2024
- Satisfied Charges ₹ 5.97 Cr
as on 24-06-2024
- Revenue 2.28%
(FY 2023)
- Profit -102.95%
(FY 2023)
- Ebitda -838.58%
(FY 2023)
- Net Worth -31.48%
(FY 2023)
- Total Assets -16.65%
(FY 2023)
About Cdymax (India) Pharma
The Corporate was formerly known as Acebright (India) Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 8.88 Cr.
The company currently has active open charges totaling ₹123.48 Cr. The company has closed loans amounting to ₹5.97 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Cdymax (India) Pharma Private Limited India is Siri Bhat as COMPANY SECRETARY. Santosh Naik and Manorama Avinash serve as directors at the Company.
- CIN/LLPIN
U85110KA1994PTC016472
- Company No.
016472
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Oct 1994
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Cdymax (India) Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Siri Bhat | Company Secretary | 28-Jul-2023 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Santosh Naik | Additional Director | 09-Jan-2024 | Current |
Manorama Avinash  | Director | 07-May-2011 | Current |
Financial Performance and Corporate Structure Insights of Cdymax (India) Pharma.
Cdymax (India) Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.28% increase. The company also saw a substantial fall in profitability, with a 102.95% decrease in profit. The company's net worth observed a substantial decline by a decrease of 31.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cdymax (India) Pharma?
In 2023, Cdymax (India) Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Nov 2021 | ₹5.99 Cr | Open |
Hdfc Bank Limited Creation Date: 20 Aug 2020 | ₹45.00 Cr | Open |
Others Creation Date: 13 Jun 2019 | ₹33.00 Cr | Open |
How Many Employees Work at Cdymax (India) Pharma?
Cdymax (India) Pharma has a workforce of 493 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cdymax (India) Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cdymax (India) Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
